Last updated on March 2020

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver


Brief description of study

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

Clinical Study Identifier: NCT02724540

Find a site near you

Start Over

Hospital Italiano de Buenos Aires

Buenos Aires, Argentina
9.74miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.